Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.

Literature DB >> 31720077

Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.

Jun-Cheng Xuhong¹, Xiao-Wei Qi¹, Yi Zhang¹, Jun Jiang¹.

Abstract

The incidence of breast cancer ranks first among female malignant tumors that affect women's health. Epidermal growth factor receptor (EGFR) family overexpression, especially human epidermal receptor2 (HER2), features prominently in breast cancer with a significant relation to poor prognosis. Currently, specific monoclonal antibodies and tyrosine kinase inhibitors (TKIs) are the two HER2 targeting strategies that have successfully improved the prognosis of patients with HER2-positive breast cancer. This paper focuses on three officially approved TKIs for HER2 breast cancer, namely, lapatinib, neratinib and pyrotinib, and systematically reviews the mechanism, safety, efficacy and resistance of these TKIs. AJCR

Entities: Chemical Disease Gene Species

Keywords: HER2-positive breast cancer; lapatinib; neratinib; pyrotinib; tyrosine kinase inhibitors

Year: 2019 PMID： 31720077 PMCID： PMC6834479

Source DB: PubMed Journal: Am J Cancer Res ISSN： 2156-6976 Impact factor: 6.166

86 in total

1. A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.

Authors: Attila A Seyhan; Usha Varadarajan; Sung Choe; Wei Liu; Terence E Ryan
Journal: Mol Biosyst Date: 2012-03-23

2. An Acquired HER2^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Authors: Ariella B Hanker; Monica Red Brewer; Jonathan H Sheehan; James P Koch; Gregory R Sliwoski; Rebecca Nagy; Richard Lanman; Michael F Berger; David M Hyman; David B Solit; Jie He; Vincent Miller; Richard E Cutler; Alshad S Lalani; Darren Cross; Christine M Lovly; Jens Meiler; Carlos L Arteaga
Journal: Cancer Discov Date: 2017-03-08 Impact factor: 39.397

3. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Authors: Paul E Goss; Ian E Smith; Joyce O'Shaughnessy; Bent Ejlertsen; Manfred Kaufmann; Frances Boyle; Aman U Buzdar; Pierre Fumoleau; William Gradishar; Miguel Martin; Beverly Moy; Martine Piccart-Gebhart; Kathleen I Pritchard; Deborah Lindquist; Yanin Chavarri-Guerra; Gursel Aktan; Erica Rappold; Lisa S Williams; Dianne M Finkelstein
Journal: Lancet Oncol Date: 2012-12-10 Impact factor: 41.316

4. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.

Authors: Rachel C Jankowitz; Jame Abraham; Antoinette R Tan; Steven A Limentani; Marni B Tierno; Laura M Adamson; Marc Buyse; Norman Wolmark; Samuel A Jacobs
Journal: Cancer Chemother Pharmacol Date: 2013-12 Impact factor: 3.333

5. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.

Authors: Xiao-qin Zhao; Jing-dun Xie; Xing-gui Chen; Hong May Sim; Xu Zhang; Yong-ju Liang; Satyakam Singh; Tanaji T Talele; Yueli Sun; Suresh V Ambudkar; Zhe-Sheng Chen; Li-wu Fu
Journal: Mol Pharmacol Date: 2012-04-04 Impact factor: 4.436

Review 6. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.

Authors: Jennifer L Hsu; Mien-Chie Hung
Journal: Cancer Metastasis Rev Date: 2016-12 Impact factor: 9.264

7. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.

Authors: H J Burstein; A M Storniolo; S Franco; J Forster; S Stein; S Rubin; V M Salazar; K L Blackwell
Journal: Ann Oncol Date: 2008-02-17 Impact factor: 32.976

8. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry.

Authors: Yunting Zhu; Liang Li; Ge Zhang; Hong Wan; Changyong Yang; Xingxing Diao; Xiaoyan Chen; Lianshan Zhang; Dafang Zhong
Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2016-08-07 Impact factor: 3.205

9. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Authors: Rachel A Freedman; Rebecca S Gelman; Jeffrey S Wefel; Michelle E Melisko; Kenneth R Hess; Roisin M Connolly; Catherine H Van Poznak; Polly A Niravath; Shannon L Puhalla; Nuhad Ibrahim; Kimberly L Blackwell; Beverly Moy; Christina Herold; Minetta C Liu; Alarice Lowe; Nathalie Y R Agar; Nicole Ryabin; Sarah Farooq; Elizabeth Lawler; Mothaffar F Rimawi; Ian E Krop; Antonio C Wolff; Eric P Winer; Nancy U Lin
Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544

10. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.

Authors: Zahi Mitri; Tina Constantine; Ruth O'Regan
Journal: Chemother Res Pract Date: 2012-12-20

29 in total

1. Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.

Authors: Xiaorong Zhong; Ping He; Jie Chen; Xi Yan; Bin Wei; Zhang Zhang; Hong Bu; Jing Li; Tinglun Tian; Qing Lv; Xiaodong Wang; Hongjiang Li; Jing Wang; Juan Huang; Jiaojiao Suo; Xiaoxiao Liu; Hong Zheng; Ting Luo
Journal: Gland Surg Date: 2022-01

Review 2. Tyrosine kinase inhibitors in breast cancer (Review).

Authors: George Iancu; Dragos Serban; Cristinel Dumitru Badiu; Ciprian Tanasescu; Mihai Silviu Tudosie; Corneliu Tudor; Daniel Ovidiu Costea; Anca Zgura; Raluca Iancu; Danut Vasile
Journal: Exp Ther Med Date: 2021-12-03 Impact factor: 2.447

Review 3. Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.

Authors: Dongqing Chen; Conagh Kelly; Tatt Jhong Haw; Janine M Lombard; Ina I C Nordman; Amanda J Croft; Doan T M Ngo; Aaron L Sverdlov
Journal: Curr Heart Fail Rep Date: 2021-11-03

4. Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer.

Authors: Chunyu Tian; Minghui Wang; Hancheng Liu; Jianping Liu; Mengze Xu; Lihui Ma
Journal: Ir J Med Sci Date: 2022-07-13 Impact factor: 2.089

Review 5. The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review.

Authors: Shafighe Asgari-Karchekani; Armin Aryannejad; Seied Asadollah Mousavi; Shirin Shahsavarhaghighi; Seyed Mohammad Tavangar
Journal: Med Oncol Date: 2022-09-29 Impact factor: 3.738